Wolbink GJ - Search Results

1

Complement activation induced by ischemia-reperfusion in humans: a study in patients undergoing partial hepatectomy.

Straatsburg IH, Boermeester MA, Wolbink GJ, van Gulik TM, Gouma DJ, Frederiks WM, Hack CE. Straatsburg IH, et al. Among authors: wolbink gj. J Hepatol. 2000 May;32(5):783-91. doi: 10.1016/s0168-8278(00)80247-0. J Hepatol. 2000. PMID: 10845665

2

Interplay of complement and cytokines in the pathogenesis of septic shock.

de Boer JP, Wolbink GJ, Thijs LG, Baars JW, Wagstaff J, Hack CE. de Boer JP, et al. Among authors: wolbink gj. Immunopharmacology. 1992 Sep-Oct;24(2):135-48. doi: 10.1016/0162-3109(92)90019-9. Immunopharmacology. 1992. PMID: 1473964 Review.

3

Angioneurotic oedema and urticaria during therapy with interleukin-2 (IL-2).

Baars JW, Wagstaff J, Hack CE, Wolbink GJ, Eerenberg-Belmer AJ, Pinedo HM. Baars JW, et al. Among authors: wolbink gj. Ann Oncol. 1992 Mar;3(3):243-4. doi: 10.1093/oxfordjournals.annonc.a058162. Ann Oncol. 1992. PMID: 1586626 Free article. No abstract available.

4

Effects on leukocytes after injection of tumor necrosis factor into healthy humans.

van der Poll T, van Deventer SJ, Hack CE, Wolbink GJ, Aarden LA, Büller HR, ten Cate JW. van der Poll T, et al. Among authors: wolbink gj. Blood. 1992 Feb 1;79(3):693-8. Blood. 1992. PMID: 1732011 Free article.

5

The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.

Baars JW, Hack CE, Wagstaff J, Eerenberg-Belmer AJ, Wolbink GJ, Thijs LG, Strack van Schijndel RJ, van der Vall HL, Pinedo HM. Baars JW, et al. Among authors: wolbink gj. Br J Cancer. 1992 Jan;65(1):96-101. doi: 10.1038/bjc.1992.18. Br J Cancer. 1992. PMID: 1733448 Free PMC article. Clinical Trial.

6

Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects.

Thijs LG, Hack CE, Strack van Schijndel RJ, Nuijens JH, Wolbink GJ, Eerenberg-Belmer AJ, Van der Vall H, Wagstaff J. Thijs LG, et al. Among authors: wolbink gj. J Immunol. 1990 Mar 15;144(6):2419-24. J Immunol. 1990. PMID: 2313099

7

Complement activation and high-dose of interleukin-2.

Thijs LG, Hack CE, Strack van Schijndel RJ, Nuijens JH, Wolbink GJ, Eerenberg-Belmer AJ, van der Vall H, Wagstaff J. Thijs LG, et al. Among authors: wolbink gj. Lancet. 1989 Aug 12;2(8659):395. doi: 10.1016/s0140-6736(89)90577-1. Lancet. 1989. PMID: 2569587 No abstract available.

8

Renal cell carcinoma and interleukin-2: a review.

Wagstaff J, Baars JW, Wolbink GJ, Hoekman K, Eerenberg-Belmer AJ, Hack CE. Wagstaff J, et al. Among authors: wolbink gj. Eur J Cancer. 1995;31A(3):401-8. doi: 10.1016/0959-8049(94)00494-p. Eur J Cancer. 1995. PMID: 7540404 Review. No abstract available.

9

Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis.

Boermeester MA, van Leeuwen PA, Coyle SM, Wolbink GJ, Hack CE, Lowry SF. Boermeester MA, et al. Among authors: wolbink gj. Arch Surg. 1995 Jul;130(7):739-48. doi: 10.1001/archsurg.1995.01430070061012. Arch Surg. 1995. PMID: 7611862 Clinical Trial.

10

Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway.

Wolbink GJ, Bollen J, Baars JW, ten Berge RJ, Swaak AJ, Paardekooper J, Hack CE. Wolbink GJ, et al. J Immunol Methods. 1993 Jul 6;163(1):67-76. doi: 10.1016/0022-1759(93)90240-8. J Immunol Methods. 1993. PMID: 7687639

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

219 results

Search Page

Filters